|  |  |
| --- | --- |
| **Pre-Program Activities** | **Pre-Works**  **Pre-Lecture 1 – Viral Hepatitis –**A summary for discovery and natural history of HCV 60 min  **Pre-Lecture 2 - End Stage Liver Disease**: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:20 am** | **Advances in the Screening and Treatment of HCV**   * Highlight of Pre-Lecture 1 * Updates on diagnostic approaches * Screening and Treatment of HCV * Caring for At-risk populations – homeless, PWID, the incarcerated * Novel FDA Approved Direct Acting Anti-virals * Clinical Cases and Discussion |
| **9:10 am** | **Hepatitis B: Epidemiology, Natural History, Testing and Treatment**   * The epidemiology of the Hepatitis B infection * Efficacies and opportunities in HBV testing and vaccination * Disease progression and impact on liver health * The efficacy of HBV Vaccination * Anti-viral therapies of HBV * The growing relationship between HBV and HDV * HBV Re-activation * Latest studies from EASL and AASLD |
| **9:40 am** | **Delta Hepatitis and Hepatitis E Update**   * Global and US perspective on the growth of Delta Hepatitis * Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards * Testing and surveillance approaches * Real world outcome studies on HDV and HEV * Management of Chronic HEV |
| **10:15 am** | ***Break and View exhibits*** |
| **10:30 am** | **End Stage Liver Disease: Recap and Clinical Cases**   * A review of Pre-course lecture on end-stage liver disease * Complications of cirrhosis * Liver transplant in the era of DAA’s * Clinical cases to illustrate HE. HRS and/or Thrombocytopenia |
| **11:05 am** | **Hepatocellular Carcinoma(HCC) - Screening and Disease Progression**   * Screening diagnostic serum assays and imaging tests * Treatment and management options: Ablation, TACE and Surgery * New studies showing cost effectiveness of surveillance post SVR * PRIUS Study (MRI vs US) Abbreviated MRI * 2023 AASLD screening guidance for liver cancer * AASLD guidance is less critical of liver biopsy for cancer detection |
| **11:40 am** | **Hepatocellular Carcinoma: New Systemic Treatment Options**   * **A case-based approach to HCC treatment** * Promising 1st and 2nd line therapies for liver cancer * New data on the benefit of downstaging * New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC * Checkpoint inhibitors and VEGE inhibitors |
| **12:15 pm** | ***Luncheon and Disease Awareness Session*** |
| **1:00 pm** | ***Dessert and View Exhibits*** |
| **1:15 pm** | **Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis**   * Epidemiology of PSC and Ursodiol and Antibiotic Treatments * Predicting outcomes and Improving Survival in PSC patients * Causes and Markers of PBC * Coping with the clinical features of PBC * Ursodeoxycholic Acid (UDCA) and Obeticholic Acid * Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar |
| **2:00 pm** | **Alcohol Associated Liver Disease**   * The growing prevalence of alcohol over-consumption and its impact on liver health * Alcohol consumption and malnutrition * Warning signs and intervention in alcohol-associated hepatitis * Promising therapeutic agents for AAH |
| ***2:30 pm*** | ***Break & View Exhibits*** |
| **2:45 pm** | **Steatotic Liver Disease: The new healthcare epidemic**   * New naming conventions for fatty liver disease: MASLD and MASH– what and why? * Epidemiology, Demographics and Diagnosis * Scoring, Staging and Management of Metabolic Liver Disease * The ‘unhealthy” rise in MASLD in the US population and What can be done * Treatment options for thrombocytopenia; including alternatives to platelet transfusion. |
| **3:20 pm** | **MASH Treatments in Practice and in Development**   * Current therapies for NASH including Updates from AASLD and EASL * Lifestyle changes as a therapy * Drugs in clinical development for NASH – Semaglutide and Resmiteron * MASH Diagnosis and Treatment case |
| **4:00 pm** | **Closing Comments, Post-test and Wrap-Up**  Program adjourns at 4:15 pm |
| **Post Program lectures:** | **Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome** 30 minutes  **Lecture 4** - **Overcoming barriers to liver health in special populations** - 45 minutes  **Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting –** 30 minutes |

**Course Director: Paul J. Pockros, MD - Scripps Health**

**Peer Review:**  **Tracy Ander, DO - University of Louisville School of Medicine**